BIM

115.2

+1.5%↑

SRT3

228.5

-0.65%↓

GXI

55.15

+2.89%↑

ICAD

20.98

-1.04%↓

BIM

115.2

+1.5%↑

SRT3

228.5

-0.65%↓

GXI

55.15

+2.89%↑

ICAD

20.98

-1.04%↓

BIM

115.2

+1.5%↑

SRT3

228.5

-0.65%↓

GXI

55.15

+2.89%↑

ICAD

20.98

-1.04%↓

BIM

115.2

+1.5%↑

SRT3

228.5

-0.65%↓

GXI

55.15

+2.89%↑

ICAD

20.98

-1.04%↓

BIM

115.2

+1.5%↑

SRT3

228.5

-0.65%↓

GXI

55.15

+2.89%↑

ICAD

20.98

-1.04%↓

Search

Almirall SA

Open

BrancheGesundheitswesen

9.66 1.26

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

9.49

Max

9.71

Schlüsselkennzahlen

By Trading Economics

Einkommen

-430K

-2.1M

Verkäufe

28M

258M

KGV

Branchendurchschnitt

187.4

57.333

EPS

0.04

Dividendenrendite

1.96

Gewinnspanne

-0.814

Angestellte

2,026

EBITDA

3.9M

45M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+44.82% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

1.96%

2.63%

Nächstes Ergebnis

12. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-26M

2B

Vorheriger Eröffnungskurs

8.4

Vorheriger Schlusskurs

9.66

Technischer Score

By Trading Central

Vertrauen

Strong Bullish Evidence

Almirall SA Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

10. Dez. 2024, 07:05 UTC

Market Talk

EU Specialty Pharma to See Product Launches But Limited Clinical Data Next Year -- Market Talk

Peer-Vergleich

Kursveränderung

Almirall SA Prognose

Kursziel

By TipRanks

44.82% Vorteil

12-Monats-Prognose

Durchschnitt 13.83 EUR  44.82%

Hoch 17 EUR

Tief 12 EUR

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Almirall SA – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

3 ratings

3

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

9.42 / 9.65Unterstützung & Widerstand

Kurzfristig

Strong Bullish Evidence

Mittelfristig

Weak Bullish Evidence

Langfristig

Weak Bullish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Almirall SA

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.